Redirecting to http://dergipark.org.tr/_fragment?_hash=s-UwadleFipXqT1hsie003q3jf-12HzL8F7Lo7Brryg&_path=id%3D648914%26_format%3Dhtml%26_locale%3Den%26_controller%3DApp%255CController%255CSite%255CArticleController%253A%253AesiArticleStats.
Other
BibTex RIS Cite

Inflammatory arthritis during immune checkpoint inhibitors therapy: case report

Year 2019, Volume: 58 Suppl: 1 (Rheumatology), 64 - 66, 25.10.2019

Tuncer Şak Burçak Karaca Figen Yargucu Zihni

https://doi.org/10.19161/etd.648914

Abstract

Nowadays, technological and scientific developments in modern medicine have enabled the emergence of new treatment strategies in the treatment of solid and hematologic malignancies. One group of these developments is, also called cancer immunotheraphy, Immune Checkpoint Inhibitors (ICI) thatareused in laterstages of tumors. ICI’s are monoclonal antibodies that allow cancercells to be killed by natural and adaptive immunity, especially T lymphocytes via activation or inhibition of the co-receptors. However, cancer immunotherapy can lead to activation of the immunecells to host’s healthy cells by eliminating self-tolerance, and to start series of immune reactions. Here, we aimed to present a case of inflammatory arthritis during cancer immunotherapy. 

Keywords

Cancer immunotherapy Immune checkpoint inhibitors ipilimumab nivolumab rheumatological complications

References

  • Duzgun O, Sarici IS, Gokcay S, et al. Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model. Acta Cir Bras 2017;32(12):1006-12.
  • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30.
  • Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
  • GirouxLeprieur E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer 2017;78:16-23.
  • Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158-68.
  • Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immunecheckpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95. doi: 10.1186/s40425-017-0300-z.
  • Teixidor E, Sais E, Vásquez CA, at al. Immune-related adverse events and atypical radiological response with checkpoint inhibitör immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget 2018;9(68):33043-9.
  • Cappelli LC, Gutierrez AK, Baer AN, at al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76(1):43-50.

Kanser immünoterapisi sırasında gelişen inflamatuvar artrit olgusu

Year 2019, Volume: 58 Suppl: 1 (Rheumatology), 64 - 66, 25.10.2019

Tuncer Şak Burçak Karaca Figen Yargucu Zihni

https://doi.org/10.19161/etd.648914

Abstract

Günümüzde modern tıpta yaşanan teknolojik ve bilimsel gelişmeler solid ve hematolojik malignitelerin tedavisinde yeni tedavi stratejilerin ortaya çıkmasını sağlamıştır. Bu gelişmelerden biri de kanser immünoterapisi olarak adlandırılan ve ileri evre tümörlerin tedavisinde kullanılan İmmün Checkpoint İnhibitörleri’nin (İCİ) kullanımıdır. İCİ denen bu grup moleküller, kanser hücrelerinin T lenfosit başta olmak üzere doğal ve adaptif immünitenin efektör hücrelerinde bulunan koreseptörlerin aktivasyon veya inhibisiyonu ile bu hücreler tarafından öldürülmesini sağlayan monoklonal antikorlardır. Bununla birlikte kanser immünoterapisi, immünite hücreleri üzerindeki manüplasyonu nedeniyle self toleransı ortadan kaldırarak konağın sağlıklı hücrelerinin de hedef haline gelmesine ve bunlara karşı bir dizi immün reaksiyon başlamasına neden olabilmektedir. Biz de kanser immünoterapisi sırasında gelişen inflamatuvar artrit olgusunu sunmayı amaçladık.

Keywords

Kanser immünoterapisi immün checkpoint inhibitörleri ipilimumab nivolumab romatolojik komplikasyonlar

References

  • Duzgun O, Sarici IS, Gokcay S, et al. Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model. Acta Cir Bras 2017;32(12):1006-12.
  • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320-30.
  • Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
  • GirouxLeprieur E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer 2017;78:16-23.
  • Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158-68.
  • Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immunecheckpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5(1):95. doi: 10.1186/s40425-017-0300-z.
  • Teixidor E, Sais E, Vásquez CA, at al. Immune-related adverse events and atypical radiological response with checkpoint inhibitör immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget 2018;9(68):33043-9.
  • Cappelli LC, Gutierrez AK, Baer AN, at al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76(1):43-50.
There are 8 citations in total.

Details

Primary Language Turkish
Journal Section Supplement
Authors

Tuncer Şak 0000-0001-6366-7038

Burçak Karaca 0000-0003-2638-1625

Figen Yargucu Zihni 0000-0001-7479-3582

Publication Date October 25, 2019
Submission Date October 19, 2018
Published in Issue Year 2019 Volume: 58 Suppl: 1 (Rheumatology)

Cite

Vancouver Şak T, Karaca B, Yargucu Zihni F. Kanser immünoterapisi sırasında gelişen inflamatuvar artrit olgusu. EJM. 2019:64-6.
 Download Cover Image